All In Biotech

NDA 204508 · Baxter Hlthcare Corp

Clinolipid 20%

Olive Oil, Soybean Oil · Intravenous · Lipid Emulsion

Priority review

Last checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Oct 3, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

133

36 Phase 3, 6 recruiting

FAERS reports

32

15 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2025.

CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLINOLIPID 20% · OLIVE OIL 16%(160GM/1000ML); SOYBEAN OIL 4% (40GM/1000ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olive Oil" as an intervention, any sponsor and status, largest first.

All 133 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • liver function test increased5
  • flushing4
  • nausea4
  • blood alkaline phosphatase increased3
  • drug ineffective3
  • pruritus3
  • urticaria3
  • alanine aminotransferase increased2
  • aspartate aminotransferase increased2
  • back pain2
  • blood triglycerides increased2
  • death2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20144
20161
20191
20202
20214
20227
20232
20242
20255
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,382 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.